RARE - Ultragenyx
Ultragenyx Logo

RARE - Ultragenyx

https://www.ultragenyx.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.

52W High
$60.37
52W Low
$25.81
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.21
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-6.46
EV/Revenue (<3 favorable)
4.30
P/S (TTM) (<3 favorable)
5.03
P/B (<3 favorable)
20.27
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
3.14%
Institutions (25–75% balanced)
101.50%
Shares Outstanding
96,372,000
Float
92,795,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
610,159,000
Gross Profit (TTM)
-167,803,008
EPS (TTM)
-5.48
Profit Margin (>10% good)
-0.87%
Operating Margin (TTM) (higher better)
-0.65%
ROE (TTM) (>15% strong)
-1.80%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.13
Momentum
Bearish momentum
Value
0.5104
Previous
0.6414
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025